We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Advanced Active Dressing Improves Wound Healing

By HospiMedica International staff writers
Posted on 24 Aug 2010
A new prototype wound care product combines advanced wound care features such as an antimicrobial barrier with properties that actively promote wound healing and tissue growth.

The Nimbus Advanced Active wound dressing is a superabsorbent dressing that provides the controlled release of a protease inhibitor, antioxidants, and epidermal growth factor to stimulate skin regeneration. More...
Based on nontoxic, long chain polymers with high charge density and high molecular weight, the dressing evokes a physical action on microbes, destroying them at the cellular level. Since the active agent is permanently bonded to the dressing surface, there is no leaching and no depletion of the antimicrobial reservoir. Also, antibiotic resistance cannot be developed, as the large size of Nimbus polymers make their internalization by the bacteria impossible. The technology is highly effective against a multitude of germs, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE), two of the most significant antibiotic-resistant organisms responsible for hospital infections.

The dressing has broad applicability to all classes of wounds, including difficult to treat thermal and chemical burns, and provides a moist wound healing environment. The Nimbus Advanced Active wound dressing is a product of Quick-Med Technologies (Gainesville, FL, USA), and has been selected by the U.S. Army for evaluation in the healing of vesicant injuries, following significant improvements in wound healing in vitro experiments with chemically injured human tissue. The next phase of the research involves animal studies that will be conducted at Battelle Memorial Institute (Columbus, OH, USA).

"Preliminary findings of the in vivo animal studies demonstrate that Nimbus Advanced Active can combine actives and control their release to enhance wound healing. These agents can perform additional functions without diminishing the dressing's antimicrobial performance,” said Jerry Olderman, vice president of research and development at QuickMed. "Nimbus Advanced Active is the ultimate multifunctional dressing, with applicability for acute and chronic wounds. Its multiple agents will aid wound healing of many types of acute and chronic injuries. We look forward to receiving the final report on the animal study confirming the results of its healing capabilities.”

Related Links:

Quick-Med Technologies
Battelle Memorial Institute




Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.